Klausner Richard 4

4 · Lyell Immunopharma, Inc. · Filed Jun 12, 2026

AI-generated summary of this filing

Updated Jun 12, 2026

Lyell (LYEL) Director Richard Klausner Receives Award of 9,250 Shares

What Happened

Richard Klausner, a director of Lyell Immunopharma (LYEL), was granted 9,250 derivative shares (reported as an award) on June 10, 2026. The filing reports an acquisition price of $0.00 for these derivative securities. This is a compensation award (not an open-market purchase or sale).

Key Details

Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (timely).
Security type: Derivative/award (Form 4 code A); 9,250 shares acquired at $0.00.
Vesting: The award vests on the earlier of (a) the date of the next annual stockholder meeting following June 10, 2026 (or immediately prior if Klausner’s directorship ends at that meeting), or (b) the first anniversary of June 10, 2026, subject to continuous service (see footnote F3).
Reported stock holdings in related trusts (per footnote F2): 7,900 shares (Klausner Family Revocable Trust) plus 12,275 + 9,716 + 12,275 shares in three Delaware trusts — totaling 42,166 shares held in those trusts; the Reporting Person disclaims beneficial ownership of the Delaware trusts except for any pecuniary interest.
Reverse split: A 1-for-20 reverse stock split was effected May 30, 2025; all share amounts reflect that split (footnote F1).

Context

This was a derivative award (likely stock option/RSU style compensation) that vests over time and does not indicate an immediate sale or purchase in the open market. Such awards are typically compensation for service and should be interpreted differently than insider purchases or sales.

Form 4

Period: 2026-06-10

Director

Transactions

Award
Option (right to buy)
[F3]
2026-06-10+9,250→ 9,250 total
Exercise: $13.22Exp: 2036-06-09→ Common Stock (9,250 underlying)

Holdings

Footnotes (3)

[F1]On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
[F2]Consists of 7,900 shares held by The Klausner Family Revocable Trust of May 8, 2014, 12,275 shares held by The Ariella Klausner Delaware Trust, 9,716 shares held by The Eli Klausner Delaware Trust and 12,275 shares held by The Olivia Klausner Delaware Trust (collectively, The Ariella Klausner Delaware Trust, The Eli Klausner Delaware Trust and The Olivia Klausner Delaware Trust, the "Delaware Trusts"). The Reporting Person is grantor and trustee of The Klausner Family Revocable Trust of May 8, 2014 and grantor of each of the Delaware Trusts. The JTC Trust Company (Delaware) Limited is the trustee of each of the Delaware Trusts. The Reporting Person disclaims beneficial ownership of all shares held by the Delaware Trusts except to any pecuniary interest therein
[F3]The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

Signature

/s/ Mark Meltz, Attorney-in-Fact|2026-06-11

1 file